Phase 3
Completed N=140
A Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg in Patients With Post-Operative Pain
Acute Moderate-to-severe Pain
Source: ClinicalTrials.gov NCT02662556 ↗
Enrolled (actual)
140
Serious AEs
0.7%
Results posted
Mar 2017
Primary outcomePrimary: Time-weighted Summed Pain Intensity Difference (SPID) Over the 12-hour Study Period (SPID12). — 36.04 units on a scale
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
This is a multicenter, open-label study in patients 40 years and older who are undergoing a surgical procedure.
Patients may receive one dose of ST 30 mcg as needed for pain management, but no more frequently than every 60 minutes, for up to 12 hours.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Time-weighted Summed Pain Intensity Difference (SPID) Over the 12-hour Study Period (SPID12). |
36.04 | — |
| SECONDARY Time-weighted Summed Pain Intensity Difference (SPID) Over the First Hour (SPID1). |
0.87 | — |
| SECONDARY Percentage of Patients Who Responded to the Global Assessments as "Excellent" or "Good" |
87.4 | — |
| SECONDARY Percentage of Healthcare Professionals Who Responded to the Global Assessments as "Excellent" or "Good" |
90.2 | — |
Eligibility Criteria
Inclusion Criteria
- Male or female patients who are 40 years of age or older.
- Patients who have undergone a surgical procedure with general anesthesia or spinal anesthesia that does not include intrathecal opioids during the operation.
- Patients classified as American Society of Anesthesiologists (ASA) class IIII (Appendix I).
Exclusion Criteria
- Patients who have taken an opioid for more than 30 consecutive days, at a daily dose of more than 15 mg of morphine (or equivalent), within the past 3 months prior to surgery (e.g. more than 3 doses per day of Vicodin®, Norco®, Lortab® with 5 mg hydrocodone per tablet).
- Patients with a positive drug of abuse screen unless the positive test result is consistent with a prescribed medication.
- Patients with a history of opioid dependence within 2 years before the start of the study, defined as meeting the DSM-IV-TR™ Criteria for Substance Dependence specified in Appendix II.
- Patients who have used any illicit drugs of abuse within five years before the start of the study.
- Patients who have abused any prescription medication or alcohol within one year before the start of the study.
- Patients with an allergy or hypersensitivity to opioids.
- Patients who are currently taking monoamine oxidase inhibitors (MAOIs) or have taken MAOIs within 14 days of the first dose of study drug.
- Patients with current sleep apnea that has been documented by a sleep laboratory study or are on home continuous positive airway pressure (CPAP).
Data sourced from ClinicalTrials.gov (NCT02662556). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.